Almquist et al. 2016 Unraveling the pharmacokinetic interaction of ticagrelor and MEDI2452 (ticagrelor antidote) by mathematical modeling. CPT Pharmacometrics & Systems Pharmacology.
Bhatt et al. 2019. Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. New England Journal of Medicine.
Buchanan et al. 2015. Structural and functional characterization of a specific antidote for ticagrelor. Blood.
Erlinge 2015. The first specific antiplatelet antidote. Blood.
Pehrsson et al. 2017. Hemostatic effects of the ticagrelor antidote MEDI2452 in pigs treated with ticagrelor on a background of aspirin. Journal of Thrombosis and Haemostasis.
Roof et al. 2015. Chronic treatment with PB1046, a stable and long-acting vasoactive intestinal peptide receptor agonist, improves cardiac and skeletal muscle function in mouse models of Duchenne Muscular Dystrophy. Poster presentation at the American Academy of Neurology Annual Meeting 2015.
del Rio et al. 2014a. Vasomera™, a Novel VPAC2-Selective Vasoactive Intestinal Peptide Agonist, Improves Arterial Elastance and Ventriculo-Arterial Coupling: Effects in Rats with Induced Diastolic Dysfunction via Renoprival Hypertension. Poster presentation at the American Heart Association High Blood Pressure Research 2014 Scientific Session.
del Rio et al. 2014b. Vasomera™, a Novel VPAC2-Selective Vasoactive Intestinal Peptide Agonist: Improved Ventriculo-Arterial Coupling and Decreased Myocardial Demand in Sheep with Induced Ischemic Heart Failure. Poster presentation at the ASFA Annual Meeting.
Free et al. 2014. A Phase 1, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety/Tolerability, Pharmacokinetic and Hemodynamic Response Following Single Ascending Subcutaneous Doses of PB1046 (Vasomera™) in Subjects with Essential Hypertension. Poster presentation at the American Heart Association Scientific Session 2014.
Chappe et al. 2014. VIP-ELP Fusion Molecules PB1120 and PB1046 Correct F508del-CFTR Dysfunction. Poster presentation at the North American Cystic Fibrosis Conference 2014.
del Rio et al. 2013. Vasomera™, a Novel VPAC2-Selective Vasoactive Intestinal Peptide Agonist. Enhanced Contractility and Decreased Myocardial Demand in Dogs with both Normal Hearts and with Pacing-Induced Dilated Cardiomyopathy. Poster presentation at American College of Cardiology 62nd Annual Scientific Session.
Youngblood et al. 2012. Vasomera™, A Novel VPAC2-Selective Vasoactive Intestinal Peptide Agonist. Evidence for Chronic Cardio-Protection in Rats with Doxorubicin-Induced Cardiomyopathy. Poster presentation at Heart Failure Society of America 16th Annual Scientific Meeting.
Yeh et al. 2012. Novel Vasoactive Intestinal Peptide-ELP Fusion Protein VPAC-Agonists. Induced Sustained Pulmonary Artery Vaso-Relaxation in Rats with Acute Hypoxia-Induced Pulmonary Hypertension. Poster presentation at American Heart Association High Blood Pressure Research 2012 Scientific Session.
del Rio et al. 2011. Evaluation of Vasomera™, A Novel VPAC2-selective VIP Agonist, on Telemetered SHR Rats: Evidence for Dose-dependent Sustained Blood Pressure Control Independent of β-AR Function. Poster presentation at American Heart Association Annual Meeting 2011.
Vasoactive Intestinal Peptide
Alshafie et al. 2014. VIP regulates CFTR membrane expression and function in Calu-3 cells by increasing its interaction with NHERF1 and P-ERM in a VPAC1- and PKCε-dependent manner. American Journal of Physiology – Cell Physiology.
Hamidi et al. 2011. VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension. Respiratory Research.
Henning and Sawmiller 2001. Vasoactive intestinal peptide: cardiovascular effects. Cardiovascular Research.
Koga et al. 2014. Role of VPAC2 receptor in monocrotaline-induced pulmonary hypertension in rats. .
McNally et al. 2015. Contemporary cardiac issues in Duchenne Muscular Dystrophy. Circulation.
Szema et al. 2013. VIP gene deletion in mice causes cardiomyopathy associated with upregulation of heart failure genes. PLOS ONE.